Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SerpinPC

Next Previous
Drug Profile

SerpinPC

Alternative Names: APC-specific serpin

Latest Information Update: 21 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Cambridge
  • Developer Centessa Pharmaceuticals
  • Class Antihaemorrhagics; Antithrombins; Serpins
  • Mechanism of Action Protein C inhibitors; Serine protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haemophilia A; Haemophilia B

Most Recent Events

  • 07 Mar 2025 Centessa Pharmaceuticals terminates the phase II PRESent-2 trial in Haemophilia A and Haemophilia B (In adolescents, In children, In adults) in USA, Armenia, Australia, Belgium, Bulgaria, Canada, France, Germany, India, Italy, Poland, South Africa, Spain, Turkey, Taiwan and UK (SC) due to business and strategic decision (NCT05789524)
  • 03 Mar 2025 ApcinteX terminates the phase II trial in Haemophilia B (In adults, In adolescents, Prevention) in Armenia, Australia, France, Germany, India, Italy, Spain, Taiwan, Turkey, United Kingdom and USA (SC) (NCT05789537)
  • 29 Jan 2025 ApcinteX Ltd terminates the Phase-III PRESent-6 trials in Haemophilia A and Haemophilia B (In adolescents, In adults, In the elderly) in Moldova, Georgia (SC) due to business and strategic decision (NCT06568302)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top